Purchase all 3 reports in this package and save $493!
Kalorama's Proteomics 50: Competing Technologies & Alliances in an Emerging Industry
November 2001

Abstract:
With the Human Genome Project in its culminating phase, scientists are turning to the task of converting the soon to be completed DNA sequence into information that will improve human medicine and health care. One of the key challenges ahead is understanding how proteins direct biological functions. Proteomics, the science of the cellular protein universe, attempts to catalog and characterize proteins, compare variations in their expression levels under different conditions (i.e., various stages of disease compared with nondisease states), study their interactions, and identify their functional roles. However, these studies will not produce a complete "proteome," or a map of an organism, because cells are always changing, as is protein expression. Scientists believe there is a powerful distinction to be made between the molecular function of an isolated protein and the function of that protein in the complex cellular environment.

The goals of proteomics in medicine are to provide the ability to predict rather than confirm disease and to construct a new, systematic way to discover drugs. A preliminary step in achieving these goals requires that researchers acquire or invent the technology to fit its aspirations. Several approaches are being studied including structural genomics, a branch of proteomics, which studies the shapes of proteins with the goal of constructing a lexicon as well as an understanding of where in the body different proteins are produced, and how each is controlled. One molecular biologist, Richard Burgess of the McArdle Laboratory for Cancer Research at the University of Wisconsin, defines the scope of proteomics as "a grab bag of activities that are all in the postgenomics or functional genomics area, or the what-do-we-need-to-know-to-make-sense-of-all-the-genomics-data arena."

Proteomics is not the study of proteins one by one, as has been done traditionally, but in an automated, large-scale manner that requires new technologies and techniques. Proteomics includes not only the identification and quantification of proteins, but also the determination of their localization, modifications, interactions, activities, and, ultimately, their function. Considerable effort is currently being devoted to the development of novel technologies to unravel the mystery of proteins.

Companies competing in the proteomics space offer technology platforms for discovering or screening drug candidates or diagnostic markers. One of the ways emerging proteomics companies fund their enterprises, is selling their services to the pharmaceutical industry through an wide array of alliances and collaborations. This report will examine competing technologies, and the alliances being formed in the proteomics arena today.

Perspectives and Profiles in Research Informatics and Systems Biology
September 2002

Abstract:
The informatics landscape is a difficult one to map. Competing suppliers, technologies, and architectures make the field confusing enough, but how informatics will ultimately shape the process of drug discovery—and indeed, the clinical practice of medicine—is an even larger question. Call it research informatics, systems biology, or bio-IT, the siliconization of the life sciences is a movement not yet fully understood.

That’s why Kalorama is taking a step back and letting leading figures in the informatics landscape ruminate on how things are shaping up. In this new sourcebook on informatics, nine thought leaders from industry, academia, and the government provide their insights, in their own words, on everything from the emerging role of the laboratorian to the necessity computing power to the new frontier of personalized medicine.

We’ve combined these individual perspectives with profiles of the top 25 companies competing in the informatics space. Each profile provides contact information, recent revenue information, core technology, key alliances, current products, pipeline products, and a strategic summary of the company’s position and outlook.

Although somewhat different from our usual comprehensive market research study, we believe that this sourcebook will enable forward-looking executives get a handle on how informatics is progressing as an industry and how it will impact the future of medicine.

Automated Compound Storage and Retrieval
September 2002

Abstract:
Fortunately, some of the same creative suppliers that pioneered HTS and ultra-HTS have begun addressing these problems. Specialty suppliers have come up with their own solutions. These range from simple, semi-automated storage boxes to totally integrated, room-sized, multi-million dollar systems. Pharma companies are pushing suppliers for better solutions. This has created a lively and dynamic market.

Automated Compound Storage and Retrieval is the first market research study to address this vital and growing marketplace. The primary audience for the report will be marketing and product planning people at companies providing products for automated compound storage and retrieval (ACSR). However, it will also be useful to companies considering entering this field, start-ups with potentially unique products and capabilities in this area and for pharma and biotech companies struggling with the issues of compound management.

The study was designed to answer the following questions about the world market for ACSR products:

• What are the problems and issues relating to compound storage and retrieval?
• How are these problems and issues affecting the success of HTS programs?
• What are some examples of ACSR solutions that have been advanced?
• How have big pharma companies utilized these solutions?
• What is big pharma looking for when designing a ACSR system?
• What types of ACSR products have suppliers made available?
• Who are the major suppliers of these products, and how are they shaping the market?
• What is the size of the market? Market growth? Major segments?
• What are the major unmet needs in ACSR? What opportunities do these needs create?
• What does the future hold for ACSR?

Related Reports:

SNP and Whole Genome Sequencing Market Research Bundle
Apr 1, 2010 - KLI2614026 - $5,995.00

Lab Automation Markets, 2nd Edition (Systems, Key Companies, Forecasts and Trends)
Mar 1, 2010 - KLI2601060 - $3,995.00

SNP Genotyping and Analysis Markets and the Future of Personalized Medicine
Feb 1, 2010 - KLI2402105 - $3,995.00

The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)
Oct 1, 2009 - KLI2435380 - $3,500.00

DNA Sequencing Equipment and Services Markets, 2nd Edition
Aug 1, 2009 - KLI2122235 - $3,800.00

Vaccines 2009: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry
Jun 1, 2009 - KLI2155319 - $3,995.00

The World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition
May 1, 2009 - KLI2218043 - $3,995.00

World Veterinary Health Products (Animal Pharmaceuticals, Vaccines, OTC and Performance Enhancers)
May 1, 2009 - KLI1829596 - $3,500.00

Pharmacodiagnostics and Personalized Medicine 2009 (Markets, Challenges, Forecasts and Key Players)
Apr 1, 2009 - KLI2128157 - $3,500.00

Liquid Chromatography Markets (LC, HPLC and UHPLC)
Mar 1, 2009 - KLI1430149 - $3,500.00